JP2010539933A5

JP2010539933A5 -

Download PDF

Info

Publication number: JP2010539933A5
Authority: JP; Japan
Prior art keywords: polypeptide; bax; bcl; compound; sahb
Prior art date: 2008-09-26
Legal status : Granted

Application number

JP2010526974A

Other languages

English (en)

Japanese (ja)

Other versions

JP5783721B2 (ja

JP2010539933A (ja

Filing date

2008-09-26

Publication date

2011-11-17

2008-09-26 Application filed filed Critical

2008-09-26 Priority claimed from PCT/US2008/011500 external-priority patent/WO2009042237A2/en

2010-12-24 Publication of JP2010539933A publication Critical patent/JP2010539933A/ja

2011-11-17 Publication of JP2010539933A5 publication Critical patent/JP2010539933A5/ja

2015-09-24 Application granted granted Critical

2015-09-24 Publication of JP5783721B2 publication Critical patent/JP5783721B2/ja

Status Active legal-status Critical Current

2028-09-26 Anticipated expiration legal-status Critical

Links

108090000765 processed proteins & peptides Proteins 0.000 claims description 385
102000004196 processed proteins & peptides Human genes 0.000 claims description 373
229920001184 polypeptide Polymers 0.000 claims description 365
150000001875 compounds Chemical class 0.000 claims description 305
102000051485 Bcl-2 family Human genes 0.000 claims description 187
108700038897 Bcl-2 family Proteins 0.000 claims description 187
238000000034 method Methods 0.000 claims description 147
230000000694 effects Effects 0.000 claims description 87
230000027455 binding Effects 0.000 claims description 82
230000003993 interaction Effects 0.000 claims description 81
125000003275 alpha amino acid group Chemical group 0.000 claims description 61
125000000539 amino acid group Chemical group 0.000 claims description 57
239000000203 mixture Substances 0.000 claims description 57
230000004913 activation Effects 0.000 claims description 55
230000000861 pro-apoptotic effect Effects 0.000 claims description 52
238000005481 NMR spectroscopy Methods 0.000 claims description 35
238000006467 substitution reaction Methods 0.000 claims description 31
WHUUTDBJXJRKMK-UHFFFAOYSA-N glutamic acid Chemical compound OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 23
238000004132 cross linking Methods 0.000 claims description 7
238000012258 culturing Methods 0.000 claims description 5
230000005298 paramagnetic effect Effects 0.000 claims description 4
102100027308 Apoptosis regulator BAX Human genes 0.000 description 316
108010040168 Bcl-2-Like Protein 11 Proteins 0.000 description 186
102100021589 Bcl-2-like protein 11 Human genes 0.000 description 185
206010028980 Neoplasm Diseases 0.000 description 159
210000004027 cell Anatomy 0.000 description 157
201000011510 cancer Diseases 0.000 description 111
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 92
235000001014 amino acid Nutrition 0.000 description 85
201000010099 disease Diseases 0.000 description 84
229940024606 amino acid Drugs 0.000 description 79
150000001413 amino acids Chemical class 0.000 description 79
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 76
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 65
230000006907 apoptotic process Effects 0.000 description 61
238000012360 testing method Methods 0.000 description 59
238000001994 activation Methods 0.000 description 55
108090000623 proteins and genes Proteins 0.000 description 52
102100032305 Bcl-2 homologous antagonist/killer Human genes 0.000 description 50
102000004169 proteins and genes Human genes 0.000 description 49
235000018102 proteins Nutrition 0.000 description 47
230000000875 corresponding effect Effects 0.000 description 46
238000011282 treatment Methods 0.000 description 46
238000003556 assay Methods 0.000 description 41
230000002424 anti-apoptotic effect Effects 0.000 description 39
230000030833 cell death Effects 0.000 description 38
102100022541 Bcl-2-related ovarian killer protein Human genes 0.000 description 37
101000899346 Homo sapiens Bcl-2-related ovarian killer protein Proteins 0.000 description 37
239000000126 substance Substances 0.000 description 35
229940124597 therapeutic agent Drugs 0.000 description 34
102100030497 Cytochrome c Human genes 0.000 description 33
108010075031 Cytochromes c Proteins 0.000 description 33
239000002246 antineoplastic agent Substances 0.000 description 33
239000000523 sample Substances 0.000 description 33
102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 31
108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 31
230000002209 hydrophobic effect Effects 0.000 description 31
230000002438 mitochondrial effect Effects 0.000 description 31
239000003814 drug Substances 0.000 description 30
102100021572 Bcl-2-binding component 3, isoforms 1/2 Human genes 0.000 description 28
241001465754 Metazoa Species 0.000 description 28
238000006384 oligomerization reaction Methods 0.000 description 28
238000002560 therapeutic procedure Methods 0.000 description 28
230000000069 prophylactic effect Effects 0.000 description 27
102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 25
108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 25
241000699670 Mus sp. Species 0.000 description 24
230000001640 apoptogenic effect Effects 0.000 description 23
230000001965 increasing effect Effects 0.000 description 23
238000004458 analytical method Methods 0.000 description 22
230000001404 mediated effect Effects 0.000 description 20
125000000217 alkyl group Chemical group 0.000 description 19
229930195733 hydrocarbon Natural products 0.000 description 19
150000002430 hydrocarbons Chemical class 0.000 description 19
230000004083 survival effect Effects 0.000 description 19
239000012634 fragment Substances 0.000 description 18
239000008194 pharmaceutical composition Substances 0.000 description 18
239000000243 solution Substances 0.000 description 17
210000001519 tissue Anatomy 0.000 description 17
102220467092 Apoptosis regulator BAX_K21E_mutation Human genes 0.000 description 16
230000002829 reductive effect Effects 0.000 description 16
238000011285 therapeutic regimen Methods 0.000 description 16
102100021590 Bcl-2-like protein 10 Human genes 0.000 description 15
101000971082 Homo sapiens Bcl-2-like protein 10 Proteins 0.000 description 15
125000003342 alkenyl group Chemical group 0.000 description 15
108700000707 bcl-2-Associated X Proteins 0.000 description 15
102000055102 bcl-2-Associated X Human genes 0.000 description 15
238000002474 experimental method Methods 0.000 description 15
230000003463 hyperproliferative effect Effects 0.000 description 15
230000005764 inhibitory process Effects 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 14
239000007788 liquid Substances 0.000 description 14
238000002703 mutagenesis Methods 0.000 description 14
231100000350 mutagenesis Toxicity 0.000 description 14
235000002639 sodium chloride Nutrition 0.000 description 14
239000004215 Carbon black (E152) Substances 0.000 description 13
230000004663 cell proliferation Effects 0.000 description 13
239000013068 control sample Substances 0.000 description 13
238000013461 design Methods 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
125000000304 alkynyl group Chemical group 0.000 description 12
230000035772 mutation Effects 0.000 description 12
230000002265 prevention Effects 0.000 description 12
-1 A1 / BFL-1 Proteins 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
239000003446 ligand Substances 0.000 description 11
239000002502 liposome Substances 0.000 description 11
238000001542 size-exclusion chromatography Methods 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
101100218425 Gallus gallus BCL2L1 gene Proteins 0.000 description 10
230000008859 change Effects 0.000 description 10
229940079593 drug Drugs 0.000 description 10
108020004707 nucleic acids Proteins 0.000 description 10
102000039446 nucleic acids Human genes 0.000 description 10
150000007523 nucleic acids Chemical class 0.000 description 10
239000012190 activator Substances 0.000 description 9
238000010171 animal model Methods 0.000 description 9
239000011324 bead Substances 0.000 description 9
230000007423 decrease Effects 0.000 description 9
FHBSGPWHCCIQPG-UHFFFAOYSA-N hydroxy-methyl-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound CS(S)(=O)=O FHBSGPWHCCIQPG-UHFFFAOYSA-N 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000007924 injection Substances 0.000 description 9
230000009467 reduction Effects 0.000 description 9
238000006722 reduction reaction Methods 0.000 description 9
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 8
238000013459 approach Methods 0.000 description 8
238000011161 development Methods 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
229910052739 hydrogen Inorganic materials 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
239000000178 monomer Substances 0.000 description 8
150000003384 small molecules Chemical class 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
239000002904 solvent Substances 0.000 description 8
108090000672 Annexin A5 Proteins 0.000 description 7
102000004121 Annexin A5 Human genes 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 7
102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 7
102100035548 Protein Bop Human genes 0.000 description 7
108050008794 Protein Bop Proteins 0.000 description 7
241000700159 Rattus Species 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
210000001185 bone marrow Anatomy 0.000 description 7
230000001413 cellular effect Effects 0.000 description 7
208000029742 colonic neoplasm Diseases 0.000 description 7
238000012790 confirmation Methods 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
208000032839 leukemia Diseases 0.000 description 7
210000004072 lung Anatomy 0.000 description 7
238000005259 measurement Methods 0.000 description 7
239000012528 membrane Substances 0.000 description 7
210000004379 membrane Anatomy 0.000 description 7
206010061289 metastatic neoplasm Diseases 0.000 description 7
210000003470 mitochondria Anatomy 0.000 description 7
238000012544 monitoring process Methods 0.000 description 7
210000000056 organ Anatomy 0.000 description 7
230000001575 pathological effect Effects 0.000 description 7
239000011148 porous material Substances 0.000 description 7
238000000746 purification Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
206010006187 Breast cancer Diseases 0.000 description 6
208000026310 Breast neoplasm Diseases 0.000 description 6
206010009944 Colon cancer Diseases 0.000 description 6
108091035707 Consensus sequence Proteins 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
241000282412 Homo Species 0.000 description 6
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
108010090804 Streptavidin Proteins 0.000 description 6
230000002159 abnormal effect Effects 0.000 description 6
230000005856 abnormality Effects 0.000 description 6
238000007792 addition Methods 0.000 description 6
235000003704 aspartic acid Nutrition 0.000 description 6
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
230000024245 cell differentiation Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
238000005094 computer simulation Methods 0.000 description 6
238000013270 controlled release Methods 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
238000001114 immunoprecipitation Methods 0.000 description 6
210000003734 kidney Anatomy 0.000 description 6
238000007726 management method Methods 0.000 description 6
238000004949 mass spectrometry Methods 0.000 description 6
230000001613 neoplastic effect Effects 0.000 description 6
231100000062 no-observed-adverse-effect level Toxicity 0.000 description 6
231100001143 noxa Toxicity 0.000 description 6
230000037361 pathway Effects 0.000 description 6
238000011002 quantification Methods 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
238000001262 western blot Methods 0.000 description 6
108090000397 Caspase 3 Proteins 0.000 description 5
102100029855 Caspase-3 Human genes 0.000 description 5
102000011727 Caspases Human genes 0.000 description 5
108010076667 Caspases Proteins 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
206010025323 Lymphomas Diseases 0.000 description 5
230000003213 activating effect Effects 0.000 description 5
150000001408 amides Chemical class 0.000 description 5
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
238000004364 calculation method Methods 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
101150039936 ced-9 gene Proteins 0.000 description 5
210000001072 colon Anatomy 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
238000001514 detection method Methods 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
239000003937 drug carrier Substances 0.000 description 5
HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 5
238000011156 evaluation Methods 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000006870 function Effects 0.000 description 5
239000000499 gel Substances 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
239000008103 glucose Substances 0.000 description 5
230000012010 growth Effects 0.000 description 5
125000001165 hydrophobic group Chemical group 0.000 description 5
206010020718 hyperplasia Diseases 0.000 description 5
238000011065 in-situ storage Methods 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
210000001700 mitochondrial membrane Anatomy 0.000 description 5
238000012900 molecular simulation Methods 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
238000011160 research Methods 0.000 description 5
238000012216 screening Methods 0.000 description 5
HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 5
CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 5
239000000725 suspension Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
230000008685 targeting Effects 0.000 description 5
230000000451 tissue damage Effects 0.000 description 5
238000002604 ultrasonography Methods 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
108010079882 Bax protein (53-86) Proteins 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
101100011368 Caenorhabditis elegans egl-1 gene Proteins 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
102000053602 DNA Human genes 0.000 description 4
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
206010027476 Metastases Diseases 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
229910005965 SO 2 Inorganic materials 0.000 description 4
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
208000009956 adenocarcinoma Diseases 0.000 description 4
235000009582 asparagine Nutrition 0.000 description 4
229960001230 asparagine Drugs 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
230000037396 body weight Effects 0.000 description 4
230000005779 cell damage Effects 0.000 description 4
208000037887 cell injury Diseases 0.000 description 4
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
230000034994 death Effects 0.000 description 4
230000002074 deregulated effect Effects 0.000 description 4
230000003831 deregulation Effects 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
239000012636 effector Substances 0.000 description 4
230000009881 electrostatic interaction Effects 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
235000013922 glutamic acid Nutrition 0.000 description 4
239000004220 glutamic acid Substances 0.000 description 4
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
238000000099 in vitro assay Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
229960000310 isoleucine Drugs 0.000 description 4
208000020816 lung neoplasm Diseases 0.000 description 4
239000000463 material Substances 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
208000010125 myocardial infarction Diseases 0.000 description 4
239000013642 negative control Substances 0.000 description 4
238000005457 optimization Methods 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
230000008569 process Effects 0.000 description 4
230000002062 proliferating effect Effects 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
241000894007 species Species 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
230000036962 time dependent Effects 0.000 description 4
238000004448 titration Methods 0.000 description 4
238000011269 treatment regimen Methods 0.000 description 4
238000002424 x-ray crystallography Methods 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
208000032467 Aplastic anaemia Diseases 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
229920002101 Chitin Polymers 0.000 description 3
241000006460 Cyana Species 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
206010058467 Lung neoplasm malignant Diseases 0.000 description 3
238000000134 MTT assay Methods 0.000 description 3
231100000002 MTT assay Toxicity 0.000 description 3
101100396287 Mus musculus Ier3 gene Proteins 0.000 description 3
201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
238000012565 NMR experiment Methods 0.000 description 3
206010061535 Ovarian neoplasm Diseases 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
206010039491 Sarcoma Diseases 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
241000282887 Suidae Species 0.000 description 3
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
239000004473 Threonine Substances 0.000 description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
206010002022 amyloidosis Diseases 0.000 description 3
125000003710 aryl alkyl group Chemical group 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
230000008901 benefit Effects 0.000 description 3
RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical group C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 3
239000012965 benzophenone Substances 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
210000000601 blood cell Anatomy 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
238000004422 calculation algorithm Methods 0.000 description 3
239000002775 capsule Substances 0.000 description 3
235000013330 chicken meat Nutrition 0.000 description 3
239000003086 colorant Substances 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
238000004590 computer program Methods 0.000 description 3
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
238000010586 diagram Methods 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
238000009510 drug design Methods 0.000 description 3
239000003797 essential amino acid Substances 0.000 description 3
235000020776 essential amino acid Nutrition 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
230000003394 haemopoietic effect Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
125000004446 heteroarylalkyl group Chemical group 0.000 description 3
125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
230000002390 hyperplastic effect Effects 0.000 description 3
238000003384 imaging method Methods 0.000 description 3
239000012133 immunoprecipitate Substances 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000006882 induction of apoptosis Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
208000028867 ischemia Diseases 0.000 description 3
230000000302 ischemic effect Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
210000002311 liver mitochondria Anatomy 0.000 description 3
201000005202 lung cancer Diseases 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000010534 mechanism of action Effects 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
238000012585 nuclear overhauser effect spectroscopy experiment Methods 0.000 description 3
150000002894 organic compounds Chemical class 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
230000007170 pathology Effects 0.000 description 3
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000004850 protein–protein interaction Effects 0.000 description 3
230000017854 proteolysis Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
239000012453 solvate Substances 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
230000009897 systematic effect Effects 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
238000001551 total correlation spectroscopy Methods 0.000 description 3
238000002054 transplantation Methods 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
239000004474 valine Substances 0.000 description 3
238000011179 visual inspection Methods 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 2
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
208000003200 Adenoma Diseases 0.000 description 2
206010002329 Aneurysm Diseases 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
208000002109 Argyria Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 description 2
208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 2
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
241000700198 Cavia Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
206010008342 Cervix carcinoma Diseases 0.000 description 2
229920000858 Cyclodextrin Polymers 0.000 description 2
102000010170 Death domains Human genes 0.000 description 2
108050001718 Death domains Proteins 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000283086 Equidae Species 0.000 description 2
206010016202 Familial Amyloidosis Diseases 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
201000008808 Fibrosarcoma Diseases 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
108010070675 Glutathione transferase Proteins 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
108060001084 Luciferase Proteins 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
241000276495 Melanogrammus aeglefinus Species 0.000 description 2
241001529936 Murinae Species 0.000 description 2
206010028570 Myelopathy Diseases 0.000 description 2
206010061309 Neoplasm progression Diseases 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
ZQXVUBDNHQEMGO-UHFFFAOYSA-N O=C1C2=C(Br)C(Br)=C(Br)C(Br)=C2C(=O)N1C1=NC=CN1 Chemical compound O=C1C2=C(Br)C(Br)=C(Br)C(Br)=C2C(=O)N1C1=NC=CN1 ZQXVUBDNHQEMGO-UHFFFAOYSA-N 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000002151 Pleural effusion Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
241000288906 Primates Species 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
208000033766 Prolymphocytic Leukemia Diseases 0.000 description 2
208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
201000000582 Retinoblastoma Diseases 0.000 description 2
239000012722 SDS sample buffer Substances 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
206010043276 Teratoma Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 2
241000021375 Xenogenes Species 0.000 description 2
230000009471 action Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
102000013529 alpha-Fetoproteins Human genes 0.000 description 2
108010026331 alpha-Fetoproteins Proteins 0.000 description 2
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
238000003782 apoptosis assay Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
230000008238 biochemical pathway Effects 0.000 description 2
238000005415 bioluminescence Methods 0.000 description 2
230000029918 bioluminescence Effects 0.000 description 2
229960000074 biopharmaceutical Drugs 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
201000000053 blastoma Diseases 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
238000004820 blood count Methods 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
230000003185 calcium uptake Effects 0.000 description 2
230000000711 cancerogenic effect Effects 0.000 description 2
HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
229910002091 carbon monoxide Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000000423 cell based assay Methods 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
201000010881 cervical cancer Diseases 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000010835 comparative analysis Methods 0.000 description 2
238000010205 computational analysis Methods 0.000 description 2
238000002591 computed tomography Methods 0.000 description 2
229960003624 creatine Drugs 0.000 description 2
239000006046 creatine Substances 0.000 description 2
201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000006471 dimerization reaction Methods 0.000 description 2
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
238000007876 drug discovery Methods 0.000 description 2
201000008184 embryoma Diseases 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
238000013401 experimental design Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
238000013213 extrapolation Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
235000013312 flour Nutrition 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
235000013305 food Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
230000002710 gonadal effect Effects 0.000 description 2
125000001475 halogen functional group Chemical group 0.000 description 2
208000014951 hematologic disease Diseases 0.000 description 2
208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000003914 insulin secretion Effects 0.000 description 2
230000010354 integration Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000009545 invasion Effects 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000013554 lipid monolayer Substances 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
208000003747 lymphoid leukemia Diseases 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000003032 molecular docking Methods 0.000 description 2
201000005962 mycosis fungoides Diseases 0.000 description 2
210000004940 nucleus Anatomy 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000035699 permeability Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
150000003905 phosphatidylinositols Chemical class 0.000 description 2
238000006303 photolysis reaction Methods 0.000 description 2
230000015843 photosynthesis, light reaction Effects 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
239000000047 product Substances 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
230000006916 protein interaction Effects 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
239000000376 reactant Substances 0.000 description 2
230000007420 reactivation Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000007423 screening assay Methods 0.000 description 2
238000002864 sequence alignment Methods 0.000 description 2
238000002922 simulated annealing Methods 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
238000010183 spectrum analysis Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
210000002536 stromal cell Anatomy 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
238000004885 tandem mass spectrometry Methods 0.000 description 2
238000002626 targeted therapy Methods 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
230000005945 translocation Effects 0.000 description 2
238000011277 treatment modality Methods 0.000 description 2
230000005740 tumor formation Effects 0.000 description 2
230000005751 tumor progression Effects 0.000 description 2
208000019553 vascular disease Diseases 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
238000002689 xenotransplantation Methods 0.000 description 2
YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 description 1
DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical compound SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
238000003979 3D HSQC-TOCSY Methods 0.000 description 1
IOJFHZXQSLNAQJ-UHFFFAOYSA-N 4-azido-2,3,5,6-tetrafluorobenzoic acid Chemical compound OC(=O)C1=C(F)C(F)=C(N=[N+]=[N-])C(F)=C1F IOJFHZXQSLNAQJ-UHFFFAOYSA-N 0.000 description 1
YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 1
KAUQJMHLAFIZDU-UHFFFAOYSA-N 6-Hydroxy-2-naphthoic acid Chemical compound C1=C(O)C=CC2=CC(C(=O)O)=CC=C21 KAUQJMHLAFIZDU-UHFFFAOYSA-N 0.000 description 1
208000023769 AA amyloidosis Diseases 0.000 description 1
208000018282 ACys amyloidosis Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010001233 Adenoma benign Diseases 0.000 description 1
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002025 Amyloidosis senile Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
206010059245 Angiopathy Diseases 0.000 description 1
201000003076 Angiosarcoma Diseases 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
206010061692 Benign muscle neoplasm Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
208000007690 Brenner tumor Diseases 0.000 description 1
206010073258 Brenner tumour Diseases 0.000 description 1
206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000009458 Carcinoma in Situ Diseases 0.000 description 1
206010007509 Cardiac amyloidosis Diseases 0.000 description 1
238000000685 Carr-Purcell-Meiboom-Gill pulse sequence Methods 0.000 description 1
229940124101 Caspase 3 inhibitor Drugs 0.000 description 1
102100026548 Caspase-8 Human genes 0.000 description 1
108090000538 Caspase-8 Proteins 0.000 description 1
102100026550 Caspase-9 Human genes 0.000 description 1
108090000566 Caspase-9 Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
201000009047 Chordoma Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108010073254 Colicins Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010048832 Colon adenoma Diseases 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
208000025212 Constitutional neutropenia Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000009798 Craniopharyngioma Diseases 0.000 description 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
101150082208 DIABLO gene Proteins 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
101100193633 Danio rerio rag2 gene Proteins 0.000 description 1
206010011878 Deafness Diseases 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
208000005431 Endometrioid Carcinoma Diseases 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
206010053776 Eosinophilic cellulitis Diseases 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
208000001382 Experimental Melanoma Diseases 0.000 description 1
208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 1
208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 1
208000007659 Fibroadenoma Diseases 0.000 description 1
241000724791 Filamentous phage Species 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
238000001535 HNCA Methods 0.000 description 1
238000001321 HNCO Methods 0.000 description 1
238000002130 HNCOCA Methods 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000001258 Hemangiosarcoma Diseases 0.000 description 1
208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 1
206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000000038 Hypoparathyroidism Diseases 0.000 description 1
206010021067 Hypopituitarism Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
206010052210 Infantile genetic agranulocytosis Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
108010076876 Keratins Proteins 0.000 description 1
102000011782 Keratins Human genes 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
238000012313 Kruskal-Wallis test Methods 0.000 description 1
LCGISIDBXHGCDW-VKHMYHEASA-N L-glutamine amide Chemical compound NC(=O)[C@@H](N)CCC(N)=O LCGISIDBXHGCDW-VKHMYHEASA-N 0.000 description 1
208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
108010053229 Lysyl endopeptidase Proteins 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
208000009018 Medullary thyroid cancer Diseases 0.000 description 1
208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
244000246386 Mentha pulegium Species 0.000 description 1
235000016257 Mentha pulegium Nutrition 0.000 description 1
235000004357 Mentha x piperita Nutrition 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
108010067028 Mitochondrial Permeability Transition Pore Proteins 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101100193635 Mus musculus Rag2 gene Proteins 0.000 description 1
241000282339 Mustela Species 0.000 description 1
201000004458 Myoma Diseases 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
206010029240 Neuritis Diseases 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
101710129178 Outer plastidial membrane protein porin Proteins 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
241000282520 Papio Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
208000002163 Phyllodes Tumor Diseases 0.000 description 1
206010071776 Phyllodes tumour Diseases 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000002664 Pleural Solitary Fibrous Tumor Diseases 0.000 description 1
229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
206010036105 Polyneuropathy Diseases 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
208000006994 Precancerous Conditions Diseases 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
208000024777 Prion disease Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108091030071 RNAI Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
208000007014 Retinitis pigmentosa Diseases 0.000 description 1
238000003111 SAR by NMR Methods 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
241000288961 Saguinus imperator Species 0.000 description 1
241000282695 Saimiri Species 0.000 description 1
208000002669 Sex Cord-Gonadal Stromal Tumors Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
206010049418 Sudden Cardiac Death Diseases 0.000 description 1
208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
238000012288 TUNEL assay Methods 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
208000002903 Thalassemia Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010044688 Trisomy 21 Diseases 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000008385 Urogenital Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
208000014070 Vestibular schwannoma Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
102100037820 Voltage-dependent anion-selective channel protein 1 Human genes 0.000 description 1
208000008526 Wells syndrome Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
206010048215 Xanthomatosis Diseases 0.000 description 1
GBJVAVGBSGRRKN-JYEBCORGSA-N Z-DEVD-FMK Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)OC)NC(=O)[C@H](CC(=O)OC)NC(=O)OCC1=CC=CC=C1 GBJVAVGBSGRRKN-JYEBCORGSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
238000002679 ablation Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
208000004064 acoustic neuroma Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
208000013228 adenopathy Diseases 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
208000024447 adrenal gland neoplasm Diseases 0.000 description 1
201000006966 adult T-cell leukemia Diseases 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000006909 anti-apoptosis Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
229940125683 antiemetic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
208000034615 apoptosis-related disease Diseases 0.000 description 1
230000005775 apoptotic pathway Effects 0.000 description 1
230000005735 apoptotic response Effects 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
108010071933 benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone Proteins 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
230000009045 body homeostasis Effects 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
238000007469 bone scintigraphy Methods 0.000 description 1
208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
201000005389 breast carcinoma in situ Diseases 0.000 description 1
208000030270 breast disease Diseases 0.000 description 1
201000003149 breast fibroadenoma Diseases 0.000 description 1
239000004126 brilliant black BN Substances 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
238000013276 bronchoscopy Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000006721 cell death pathway Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
210000004671 cell-free system Anatomy 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
208000025434 cerebellar degeneration Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000010428 chromatin condensation Effects 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000021572 chromosome movement towards spindle pole Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000001142 circular dichroism spectrum Methods 0.000 description 1
238000000749 co-immunoprecipitation Methods 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
238000002052 colonoscopy Methods 0.000 description 1
230000004732 colorectal carcinogenesis Effects 0.000 description 1
208000016576 colorectal neuroendocrine tumor G1 Diseases 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000000205 computational method Methods 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000006352 cycloaddition reaction Methods 0.000 description 1
208000002445 cystadenocarcinoma Diseases 0.000 description 1
208000007321 cystadenofibroma Diseases 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000003936 denaturing gel electrophoresis Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
238000003255 drug test Methods 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000002296 dynamic light scattering Methods 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
208000030172 endocrine system disease Diseases 0.000 description 1
210000001900 endoderm Anatomy 0.000 description 1
201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
208000028730 endometrioid adenocarcinoma Diseases 0.000 description 1
238000001839 endoscopy Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
210000005081 epithelial layer Anatomy 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
230000034725 extrinsic apoptotic signaling pathway Effects 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
206010016629 fibroma Diseases 0.000 description 1
230000003176 fibrotic effect Effects 0.000 description 1
238000001917 fluorescence detection Methods 0.000 description 1
238000002875 fluorescence polarization Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
230000003325 follicular Effects 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000009368 gene silencing by RNA Effects 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
206010061989 glomerulosclerosis Diseases 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
201000000079 gynecomastia Diseases 0.000 description 1
210000002768 hair cell Anatomy 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000010370 hearing loss Effects 0.000 description 1
231100000888 hearing loss Toxicity 0.000 description 1
208000016354 hearing loss disease Diseases 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
201000002222 hemangioblastoma Diseases 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
238000004896 high resolution mass spectrometry Methods 0.000 description 1
230000003118 histopathologic effect Effects 0.000 description 1
238000007489 histopathology method Methods 0.000 description 1
235000001050 hortel pimenta Nutrition 0.000 description 1
230000005661 hydrophobic surface Effects 0.000 description 1
208000015210 hypertensive heart disease Diseases 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
208000003532 hypothyroidism Diseases 0.000 description 1
230000002989 hypothyroidism Effects 0.000 description 1
238000005286 illumination Methods 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000010185 immunofluorescence analysis Methods 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
201000004933 in situ carcinoma Diseases 0.000 description 1
230000005918 in vitro anti-tumor Effects 0.000 description 1
230000005917 in vivo anti-tumor Effects 0.000 description 1
238000011503 in vivo imaging Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
206010022498 insulinoma Diseases 0.000 description 1
238000012482 interaction analysis Methods 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000000185 intracerebroventricular administration Methods 0.000 description 1
201000003159 intraductal papilloma Diseases 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000002601 intratumoral effect Effects 0.000 description 1
230000034727 intrinsic apoptotic signaling pathway Effects 0.000 description 1
206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
201000010985 invasive ductal carcinoma Diseases 0.000 description 1
206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
RCRODHONKLSMIF-UHFFFAOYSA-N isosuberenol Natural products O1C(=O)C=CC2=C1C=C(OC)C(CC(O)C(C)=C)=C2 RCRODHONKLSMIF-UHFFFAOYSA-N 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
238000005304 joining Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
208000037393 large granular lymphocyte leukemia Diseases 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000012633 leachable Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
244000144972 livestock Species 0.000 description 1
201000011059 lobular neoplasia Diseases 0.000 description 1
230000004807 localization Effects 0.000 description 1
208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
239000003580 lung surfactant Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
208000012804 lymphangiosarcoma Diseases 0.000 description 1
210000000207 lymphocyte subset Anatomy 0.000 description 1
201000000564 macroglobulinemia Diseases 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
208000006178 malignant mesothelioma Diseases 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
241001515942 marmosets Species 0.000 description 1
208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
244000309715 mini pig Species 0.000 description 1
208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
230000006676 mitochondrial damage Effects 0.000 description 1
230000006667 mitochondrial pathway Effects 0.000 description 1
230000006540 mitochondrial respiration Effects 0.000 description 1
230000008965 mitochondrial swelling Effects 0.000 description 1
239000003607 modifier Substances 0.000 description 1
230000000897 modulatory effect Effects 0.000 description 1
238000000329 molecular dynamics simulation Methods 0.000 description 1
230000004001 molecular interaction Effects 0.000 description 1
238000000324 molecular mechanic Methods 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
238000009126 molecular therapy Methods 0.000 description 1
201000002335 monodermal teratoma Diseases 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
208000022669 mucinous neoplasm Diseases 0.000 description 1
108091005763 multidomain proteins Proteins 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
125000001419 myristoyl group Chemical class O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
229950004847 navitoclax Drugs 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
208000012108 neoplastic polyp Diseases 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
238000000033 nuclear magnetic resonance titration Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000007968 orange flavor Substances 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
208000025207 ovarian monodermal teratoma Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
208000021255 pancreatic insulinoma Diseases 0.000 description 1
208000004019 papillary adenocarcinoma Diseases 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
238000001408 paramagnetic relaxation enhancement Methods 0.000 description 1
239000004177 patent blue V Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
MLBYLEUJXUBIJJ-UHFFFAOYSA-N pent-4-ynoic acid Chemical compound OC(=O)CCC#C MLBYLEUJXUBIJJ-UHFFFAOYSA-N 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
208000024724 pineal body neoplasm Diseases 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
201000003437 pleural cancer Diseases 0.000 description 1
201000003144 pneumothorax Diseases 0.000 description 1
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
208000019629 polyneuritis Diseases 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000012254 powdered material Substances 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
208000035803 proliferative type breast fibrocystic change Diseases 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
229940043274 prophylactic drug Drugs 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
230000004853 protein function Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000000575 proteomic method Methods 0.000 description 1
239000010453 quartz Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000011363 radioimmunotherapy Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
239000013643 reference control Substances 0.000 description 1
208000016691 refractory malignant neoplasm Diseases 0.000 description 1
230000025915 regulation of apoptotic process Effects 0.000 description 1
102000037983 regulatory factors Human genes 0.000 description 1
108091008025 regulatory factors Proteins 0.000 description 1
230000008439 repair process Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
208000008864 scrapie Diseases 0.000 description 1
208000018964 sebaceous gland cancer Diseases 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
208000002320 spinal muscular atrophy Diseases 0.000 description 1
GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
238000003756 stirring Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
229940043263 traditional drug Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
206010044412 transitional cell carcinoma Diseases 0.000 description 1
201000007905 transthyretin amyloidosis Diseases 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
201000007423 tubular adenocarcinoma Diseases 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
238000004104 two-dimensional total correlation spectroscopy Methods 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
239000002691 unilamellar liposome Substances 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
208000037964 urogenital cancer Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
229910052720 vanadium Inorganic materials 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
230000037314 wound repair Effects 0.000 description 1
238000012447 xenograft mouse model Methods 0.000 description 1
238000001086 yeast two-hybrid system Methods 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1
FHQVHHIBKUMWTI-OTMQOFQLSA-N {1-hexadecanoyl-2-[(Z)-octadec-9-enoyl]-sn-glycero-3-phospho}ethanolamine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC FHQVHHIBKUMWTI-OTMQOFQLSA-N 0.000 description 1

JP2010526974A 2007-09-26 2008-09-26 Ｂｃｌ−２ファミリーポリペプチドを調節する方法及び組成物 Active JP5783721B2 (ja)